相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation
Caroline G. Elmer-Lyon et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2020)
Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?
Howard B. Goldman et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2019)
Updating the evidence on drugs to treat overactive bladder: a systematic review
Frances C. Hsu et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2019)
Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder
Shilpa Iyer et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2019)
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
David Staskin et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2018)
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis
Con Kelleher et al.
EUROPEAN UROLOGY (2018)
Efficacy of pelvic floor muscle training in women with overactive bladder syndrome: a systematic review
Silvia Monteiro et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2018)
Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder
Chung-Cheng Wang et al.
LUTS-LOWER URINARY TRACT SYMPTOMS (2017)
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY)
P. Abrams et al.
WORLD JOURNAL OF UROLOGY (2017)
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)
Sender Herschorn et al.
BJU INTERNATIONAL (2017)
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)
Marcus J. Drake et al.
EUROPEAN UROLOGY (2016)
分享论文
